ClinicalTrials.gg
CompletedNCT03335540ADVISEUpdated Sep 26, 2022

An Adaptive Study to Match Patients With Solid Tumors to Various Immunotherapy Combinations Based Upon a Broad Biomarker Assessment

A Phase 1 interventional study of Nivolumab and Relatlimab in Advanced Cancer, sponsored by Bristol-Myers Squibb. Completed at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-09-26.

Sponsored by Bristol-Myers Squibb · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Mar 2021, 5 years 7 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to evaluate the treatment of solid tumors with various immunotherapy combinations. The treatment will be determined based upon a broad biomarker assessment.

02

Conditions studied

  • Advanced Cancer
03

In context

Lead sponsor

Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.

Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must have an performance status of less than or equal to 1
  • Participants must have had prior therapy;Participants who have received or neoadjuvant anti-PD(L)1 therapy andprogressed within 6 months of completing therapy will be considered IO .
  • Participants must have at least 2 lesions with as defined by Version 1.1

Exclusion criteria

Exclusion Criteria:

  • Participants with suspected, known, or progressive , have untreated CNS metastases, or have the CNS as the only site of disease
  • Participants with carcinomatous meningitis
  • Participants with other active requiring concurrent intervention

Other protocol defined inclusion/exclusion criteria could apply

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Arm B

    Combination therapy determined by biomarker assessment

    Biological: Nivolumab · Biological: Relatlimab

  • Experimental
    Arm C

    Combination therapy determined by biomarker assessment

    Biological: Nivolumab · Biological: Cabiralizumab

  • Experimental
    Arm D

    Combination therapy determined by biomarker assessment

    Biological: Nivolumab · Biological: Ipilimumab

  • Experimental
    Arm F

    Combination therapy determined by biomarker assessment

    Biological: Nivolumab · Drug: IDO1 Inhibitor

  • Experimental
    Arm G

    Combination therapy determined by biomarker assessment

    Biological: Nivolumab · Radiation: Radiation Therapy

Interventions

  • BiologicalNivolumab

    Specified dose on specified day

    Also known as: BMS-936558

  • BiologicalRelatlimab

    Specified dose on specified day

    Also known as: BMS-986016

  • BiologicalCabiralizumab

    Specified dose on specified day

    Also known as: BMS-986227, FPA008

  • BiologicalIpilimumab

    Specified dose on specified day

    Also known as: BMS-734016

  • DrugIDO1 Inhibitor

    Specified dose on specified day

    Also known as: BMS-986205

  • RadiationRadiation Therapy

    Specified dose on specified day

06

What researchers measure

Primary outcomes

  1. Number of participants with qualified tumor biopsy specimen at baseline

    An adequate quality tumor biopsy providing sufficient information prior to choosing a combination immunotherapy/Stereotactic Body Radiation Therapy (SBRT)

    Time frame: Up to 28 days

Secondary outcomes

  1. Percent of change from baseline in histopathologic features

    Time frame: Up to 4 years

  2. Percent of change from baseline in biomarker expression patterns

    Time frame: Up to 4 years

  3. Number of Adverse Events (AEs)

    Time frame: Up to 4 years

  4. Number of Serious Adverse Events (SAEs)

    Time frame: Up to 4 years

  5. Number of Laboratory Abnormalities

    Any laboratory test result that is clinically significant or meets the definition of an SAE, requires the participant to have study treatment discontinued, or receive specific corrective therapy

    Time frame: Up to 4 years

  6. Number of Adverse Events(AEs) leadind to discontinutaion

    Number of Adverse Events leadind to discontinutaion

    Time frame: up to 4 years

  7. Number of Deaths

    Time frame: up to 4 years

07

Study locations

4 sites
  • Local Institution - 0001
    Chicago, Illinois 60637, United States
  • University of Chicago
    Chicago, Illinois 60637, United States
  • Local Institution - 0002
    Baltimore, Maryland 21287, United States
  • Local Institution - 0003
    Pittsburgh, Pennsylvania 15232, United States
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2018 to primary completion in Mar 2021, 34 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 6, 2017
First posted
Nov 7, 2017
StartActual
May 7, 2018
Primary completionActual
Mar 31, 2021
CompletionActual
Aug 25, 2021
Last update
Sep 26, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 26, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03335540
Responsible party
Sponsor
First posted
Nov 7, 2017
Start date
May 7, 2018
Primary completion
Mar 31, 2021
Completion
Aug 25, 2021
Last update
Sep 26, 2022

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Relatlimab · Cabiralizumab

Start the discussion